SCHEDULE: Omega Fund Discloses 8.4% Stake in ImageneBio

Omega Fund VI, L.P. and associated entities have reported beneficial ownership of 8.4% of ImageneBio, Inc. common stock following recent financing.

Summary

• Omega Fund VI, L.P., along with Omega Fund VI GP, L.P., Omega Fund VI GP Manager, Ltd., Claudio Nessi, and Otello Stampacchia (collectively, the "Reporting Persons"), have filed a Schedule 13D indicating beneficial ownership of 935,843 shares of ImageneBio, Inc. common stock, representing 8.4% of the outstanding shares.
• This ownership stake was primarily acquired through participation in the 2025 PIPE Financing and the recent 2026 PIPE Financing.
• Otello Stampacchia also holds an additional 379 shares directly and serves on the Issuer's board of directors.
• The Reporting Persons state their acquisition of shares was for investment purposes in the ordinary course of business.
• They may engage in discussions with the Issuer's management and board regarding various strategic and corporate matters, including potential acquisitions, dispositions, business changes, or governance adjustments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on an investment stake and potential future discussions rather than specific operational or financial performance of the company.

Positives

• Significant investment by Omega Fund VI, L.P. in ImageneBio, Inc., indicating confidence in the company's prospects.
• Participation in two PIPE financings (2025 and 2026) totaling substantial capital for the company.
• Otello Stampacchia's role on the board of directors provides direct oversight and engagement with the company's strategy.

Negatives

• The filing does not contain specific financial performance data for ImageneBio, Inc., making it difficult to assess the company's current operational health.
• The potential for future discussions regarding changes to business, governance, or capitalization could introduce uncertainty for other stakeholders.

Risks

• The Reporting Persons may engage in discussions that could lead to changes in the Issuer's business, operations, governance, management, strategy, or capitalization.
• The Reporting Persons may acquire additional securities, potentially increasing their influence or control.
• The Reporting Persons may consider various alternative courses of action, including extraordinary corporate transactions, asset sales, or changes to the board or management, which could impact the company's direction and value.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from ImageneBio, Inc. regarding its future financial performance or operations. However, the Reporting Persons indicate they may engage in discussions that could lead to changes in the company's business, strategy, or capitalization.

Management Comments

• The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business.
• The Reporting Persons, either directly or indirectly through Stampacchia, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders.
• The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing by Omega Fund VI, L.P. highlights significant investor activity in the biotechnology sector, particularly concerning PIPE (Private Investment in Public Equity) financings. Such filings are common when investment funds accumulate substantial stakes, often signaling strategic interest or potential influence over a company's direction.

Stakeholder Impact

• Shareholders: The increased stake by Omega Fund and potential for strategic discussions could influence future share price and corporate direction. The PIPE financings provide capital, which can be positive for growth, but also dilutive.
• Management and Board: The Reporting Persons may engage in discussions that could lead to changes in management or the board of directors.
• Creditors: Capital raises can strengthen the company's financial position, potentially benefiting creditors, but significant strategic shifts could alter risk profiles.

Next Steps

• The Issuer is obligated to file a registration statement for the resale of Warrant Shares from the 2026 PIPE Financing within three business days following August 1, 2026, subject to allowable delays.
• The Reporting Persons may engage in discussions with the Issuer's board, management, or other stockholders regarding various strategic and corporate matters.
• The Reporting Persons may acquire additional securities of the Issuer through various methods.

Key Dates

Recommendation

The filing is a Schedule 13D, primarily disclosing an investment stake and potential future strategic discussions by Omega Fund. It does not contain specific financial results or forward-looking guidance from ImageneBio, Inc. itself. While the capital raises are positive for funding operations, the lack of performance data and the potential for management/strategy changes warrant a 'hold' recommendation pending further information on the company's operational progress and the impact of Omega Fund's involvement.

Keywords

Schedule 13D, Omega Fund, ImageneBio, Otello Stampacchia, PIPE Financing, Beneficial Ownership, Securities Filing, Investment, Corporate Governance